

Neovascular Age-related Macular Degeneration

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Trial Status
Recruiting

Trial Runs In
1 Countries

Trial Identifier
NCT05562947 YR42983

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT05562947 YR42983
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥50 Years & ≤ 80 Years

Healthy Volunteers
No